Tyme Technologies (NSDQ:TYME) announced today that it received a U.S. patent for its metabolomic drug delivery platform. Bedminster, N.J.-based Tyme’s additional patent claims related to the metabolomic technology platform (U.S. Patent No. 11,058,638) involves the targeted delivery of therapeutics to cancer cells. The company’s technology fuses the tyrosine isomer racemetryosine (α-methylparatyrosine) with a second therapeutic […]
Research & Development
Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’
As we enter what may be the “new normal,” Dexcom’s CEO bets the company can pave the way in continuous glucose monitoring. Dexcom (NSDQ:DXCM), like any company seeking to innovate, remains in a state of perpetual forward motion. That’s the way chair, president & CEO Kevin Sayer views it, anyway. As the company looks toward […]
Diabetes Center Berne launches open innovation challenge for diabetes tech
The Diabetes Center Berne today announced the launch of an initiative to develop technology to address the treatment of diabetes. DCB is seeking innovators, co-creators, scientists and members of the diabetes community to join the company’s innovation challenge and join its community of diabetes technology developers. The center requested anyone ranging from members of start-ups, […]
MedinCell to begin regulatory development of long-acting injectable malaria treatment
MedinCell announced that its long-acting injectable malaria treatment is ready to enter into the stages of regulatory development. Montpellier, France–based MedinCell conducted an in vivo proof of concept on cattle that demonstrated three-month mosquitocidal effectiveness in the injectable, long-acting formulation of Ivermectin using the company’s BEPO delivery technology. The company designed the investigational mdc-STM product […]
Lyra inks $135M partnership to expand chronic rhinosinusitis treatment in Asia
Lyra Therapeutics (NSDQ:LYRA) announced today that it entered into a strategic partnership with LianBio for its LYR-210 treatment for chronic rhinosinusitis. Watertown, Mass.–based Lyra, which develops the LYR-210 therapeutic to be locally delivered by its proprietary XTreo platform, could receive up to $135 million in total payments through the strategic partnership and exclusive license agreement […]
Nanoform, Celanese partner to develop nanoparticle-enabled drug delivery
Nanoform announced today that it partnered with Celanese to explore the use of their technologies in nanoparticle-enabled drug delivery. Helsinki-based Nanoform said the goal of the collaboration is to assess the combination of its nanoparticle platform technologies with Celanese’s VitalDose EVA copolymer delivery technology for drug-eluting implants, according to a news release. Both companies intend […]
UC Riverside researchers tout piezoelectric polymer for drug delivery
Researchers at the University of California, Riverside, are touting a polymer-based membrane as a potential drug delivery platform. The researchers developed the membrane made from threads of a polymer commonly used in vascular sutures, according to the university’s website. The membrane can be loaded with therapeutic drugs and implanted in the body before mechanical forces […]
BrightInsight raises $101M for its pre-built digital health platform
BrightInsight announced today that it’s raised $101 million in a Series C round led by VC firm General Catalyst. The money will go toward more hiring and further accelerating the work BrightInsight is conducting with customers to support their digital health product launches. The San Jose, Calif.–based company offers a turnkey digital health platform for […]
Oramed forms joint venture to develop oral COVID-19 vaccines with POD delivery tech
Oramed Pharmaceuticals (NSDQ:ORMP) announced today that it is forming a joint venture to develop novel oral COVID-19 vaccines. New York-based Oramed entered into definitive agreements to form Oravax Medical, which is based on Oramed’s proprietary POD (protein oral delivery) technology and Premas Biotech’s novel vaccine technology, according to a news release. Oravax’s COVID-19 vaccine candidate […]
NeuroRX, TFF Pharmaceuticals enter feasibility agreement for Zyesami dry powder for COVID-19
NeuroRx and TFF Pharmaceuticals (NSDQ:TFFP) announced a feasibility agreement for the former’s Zyesami therapeutic. Zyesami (aviptadil, synthetic VIP) materials are set to be delivered to TFF to perform feasibility formulation work and testing in an effort to identify an optimal, long-term, stable formulation of Zyesami into a dry powder form for aerosol delivery directly to […]
